|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:MYO5A-B2M (FusionGDB2 ID:56366) |
Fusion Gene Summary for MYO5A-B2M |
Fusion gene summary |
Fusion gene information | Fusion gene name: MYO5A-B2M | Fusion gene ID: 56366 | Hgene | Tgene | Gene symbol | MYO5A | B2M | Gene ID | 4644 | 567 |
Gene name | myosin VA | beta-2-microglobulin | |
Synonyms | GS1|MYH12|MYO5|MYR12 | IMD43 | |
Cytomap | 15q21.2 | 15q21.1 | |
Type of gene | protein-coding | protein-coding | |
Description | unconventional myosin-Vadilute myosin heavy chain, non-musclemyosin Vmyosin VA (heavy chain 12, myoxin)myosin, heavy polypeptide kinasemyosin-12myosin-Vamyoxin | beta-2-microglobulinbeta chain of MHC class I moleculesbeta-2-microglobin | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | Q9Y4I1 | P61769 | |
Ensembl transtripts involved in fusion gene | ENST00000399231, ENST00000356338, ENST00000358212, ENST00000399233, ENST00000553916, | ENST00000558401, ENST00000559916, ENST00000544417, ENST00000559220, | |
Fusion gene scores | * DoF score | 13 X 13 X 6=1014 | 64 X 31 X 17=33728 |
# samples | 12 | 71 | |
** MAII score | log2(12/1014*10)=-3.07895134139482 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(71/33728*10)=-5.56998393724517 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: MYO5A [Title/Abstract] AND B2M [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | MYO5A(52820976)-B2M(45007620), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | MYO5A-B2M seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. MYO5A-B2M seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. MYO5A-B2M seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | B2M | GO:0002726 | positive regulation of T cell cytokine production | 24643698 |
Tgene | B2M | GO:0007611 | learning or memory | 26147761 |
Tgene | B2M | GO:0050680 | negative regulation of epithelial cell proliferation | 28213472 |
Tgene | B2M | GO:0050768 | negative regulation of neurogenesis | 26147761 |
Tgene | B2M | GO:0090647 | modulation of age-related behavioral decline | 26147761 |
Tgene | B2M | GO:1900121 | negative regulation of receptor binding | 9465039 |
Tgene | B2M | GO:1990000 | amyloid fibril formation | 28468825 |
Tgene | B2M | GO:2000774 | positive regulation of cellular senescence | 28213472 |
Tgene | B2M | GO:2000978 | negative regulation of forebrain neuron differentiation | 26147761 |
Fusion gene breakpoints across MYO5A (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across B2M (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | STAD | TCGA-HU-A4GY | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Top |
Fusion Gene ORF analysis for MYO5A-B2M |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000399231 | ENST00000558401 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000399231 | ENST00000559916 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000399231 | ENST00000544417 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
5CDS-intron | ENST00000399231 | ENST00000559220 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000356338 | ENST00000558401 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000356338 | ENST00000559916 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000356338 | ENST00000544417 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
5CDS-intron | ENST00000356338 | ENST00000559220 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
intron-3CDS | ENST00000358212 | ENST00000558401 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
intron-3CDS | ENST00000358212 | ENST00000559916 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
intron-3CDS | ENST00000358212 | ENST00000544417 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
intron-intron | ENST00000358212 | ENST00000559220 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000399233 | ENST00000558401 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000399233 | ENST00000559916 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000399233 | ENST00000544417 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
5CDS-intron | ENST00000399233 | ENST00000559220 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000553916 | ENST00000558401 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000553916 | ENST00000559916 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
Frame-shift | ENST00000553916 | ENST00000544417 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
5CDS-intron | ENST00000553916 | ENST00000559220 | MYO5A | chr15 | 52820976 | - | B2M | chr15 | 45007620 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for MYO5A-B2M |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for MYO5A-B2M |
Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MYO5A | B2M |
FUNCTION: Processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. Involved in melanosome transport. Also mediates the transport of vesicles to the plasma membrane. May also be required for some polarization process involved in dendrite formation. {ECO:0000269|PubMed:10448864}. | FUNCTION: Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation (PubMed:25356553). {ECO:0000269|PubMed:25356553}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for MYO5A-B2M |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for MYO5A-B2M |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MYO5A-B2M |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | B2M | P61769 | DB09130 | Copper | Small molecule | Approved|Investigational | |
Tgene | B2M | P61769 | DB09130 | Copper | Small molecule | Approved|Investigational | |
Tgene | B2M | P61769 | DB09130 | Copper | Small molecule | Approved|Investigational |
Top |
Related Diseases for MYO5A-B2M |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | MYO5A | C1836573 | GRISCELLI SYNDROME, TYPE 3 | 2 | GENOMICS_ENGLAND;ORPHANET |
Hgene | MYO5A | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Hgene | MYO5A | C0398794 | Hypopigmentation-immunodeficiency disease | 1 | GENOMICS_ENGLAND |
Hgene | MYO5A | C1859194 | GRISCELLI SYNDROME, TYPE 1 | 1 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | MYO5A | C1860157 | Elejalde Disease | 1 | GENOMICS_ENGLAND;ORPHANET |
Hgene | MYO5A | C4721453 | Peripheral Nervous System Diseases | 1 | CTD_human |
Tgene | B2M | C0022658 | Kidney Diseases | 3 | CTD_human |
Tgene | B2M | C0022660 | Kidney Failure, Acute | 3 | CTD_human |
Tgene | B2M | C1565662 | Acute Kidney Insufficiency | 3 | CTD_human |
Tgene | B2M | C2609414 | Acute kidney injury | 3 | CTD_human |
Tgene | B2M | C1855796 | Hypoproteinemia, Hypercatabolic | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | B2M | C0004364 | Autoimmune Diseases | 1 | CTD_human |
Tgene | B2M | C0013221 | Drug toxicity | 1 | CTD_human |
Tgene | B2M | C0018799 | Heart Diseases | 1 | CTD_human |
Tgene | B2M | C0020455 | Hypergammaglobulinemia | 1 | CTD_human |
Tgene | B2M | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Tgene | B2M | C0041755 | Adverse reaction to drug | 1 | CTD_human |
Tgene | B2M | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
Tgene | B2M | C0079774 | Peripheral T-Cell Lymphoma | 1 | CTD_human |
Tgene | B2M | C0268389 | Amyloidosis, familial visceral | 1 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | B2M | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
Tgene | B2M | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Tgene | B2M | C1858266 | Bare Lymphocyte Syndrome, Type I | 1 | ORPHANET |
Tgene | B2M | C4302669 | Autosomal dominant beta2-microglobulinic amyloidosis | 1 | ORPHANET |